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ABSTRACT 
The purpose of this study is to determine the prevalence of Escherichia coli as an aetiologic agent in bacterial 
infections and its antimicrobial susceptibility patterns to ciprofloxacin, ofloxacin, norfloxacin, perfloxacin, 
gentamycin and cotrimoxazole as a guide for empiric therapy. A retrospective study was carried out using a 
clinical microbiology laboratory in Nigeria.  Data retrieved include number of E. coli isolates, sources of the 
isolates and their antimicrobial susceptibility to various fluoroquinolones, gentamycin and cotrimoxazole 
between 2005 and 2009. Statistical analysis was carried out using SPSS version 14, Chicago IL. Out of a total of 
906 bacterial isolates, E. coli accounted for 23 % (211) of the isolates. Thirty-eight percent (38.39 %) was isolated 
from urine samples, 27.96 % from high vaginal swab samples, 24.17 % from stool samples, 0.95% from urethra 
swabs, 1.9% from wound swabs and 6.6% from semen samples. There was poor level of susceptibility to 
norfloxacin (2.2%) and cotrimoxazole (23.7%), susceptibility to ofloxacin, ciprofloxacin and pefloxacin were 
51.1%, 54.7% and 52.5% respectively, that of gentamycin was 51.8%. The trends across the years showed a 
significant increase in susceptibility to ciprofloxacin, pefloxacin and ofloxacin in 2007 after which it started 
reducing, while norfloxacin’s susceptibility was low across the five years with maximum susceptibility at 9.1% in 
2006. There was an increase in susceptibility to gentamycin as the susceptibility levels of the fluoroquinolones 
were reducing. There should be continuous surveillance of antimicrobial susceptibility patterns and empiric 
treatment with fluoroquinolones discouraged, especially for non urinary tract infections. 
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INTRODUCTION 
Antimicrobial resistance is a worldwide problem 
and it is one of the greatest challenges to health care 
delivery[1].  There is tremendous variability in 
antimicrobial resistance patterns not only among 
pathogens causing various clinical infections but 
also in different geographical regions and over time 
[2].  Surveillance of susceptibility patterns of 
pathogens to antimicrobial agents is therefore, 
important in the monitoring and detection of 
increase in resistance [3-5].  It is very helpful for 
clinicians in prescribing antimicrobial agents 
especially in cases where empiric treatment is 
employed. In Nigeria, as is the case in many 
developing countries, empiric therapy is often 
employed as a result of inadequate staffing and 
laboratory facilities [6]. 
E.coli has been identified as a predominant 
pathogen for various bacterial infections especially  
 
urinary tract infections [7-11].  Fluoroquinolones 
have been proven to be highly effective broad 
spectrum agents especially against those infections 
caused by Gram-negative organisms.[12] Due to high 
resistance to cotrimoxazole, fluoroquinolones 
became the first drug of choice for empiric 
treatment of urinary tract infections and other 
infections caused by Gram-negative bacteria and its 
widespread use has resulted in the rise in their 
resistance.[13]  Despite the regular use of empiric 
treatment in Nigeria, data on antimicrobial 
susceptibility patterns of various pathogens are 
scant. This study was therefore carried out to 
determine prevalence of E. coli as an aetiologic 
agent in community acquired bacterial infections 
and its antimicrobial susceptibility patterns to 
different fluoroquinolones, as well as gentamycin 






This was a single centre retrospective study done 
between January 2005 and December 2009 in a 
clinical microbiology laboratory in South-south 
Nigeria. Data retrieved from microbiology 
laboratory records included number of E. coli 
isolates, sources of the isolates and antimicrobial 
susceptibility to ciprofloxacin, ofloxacin, pefloxacin, 
and norfloxacin (fluoroquinolones) and also 
cotrimoxazole and gentamycin, popularly used in 
the country for the treatment of bacterial infections. 
Isolates collected from the same specimen source 
within seven days were excluded. Samples were 
inoculated on blood agar, MacConkey agar and 
urine samples on cystine lactose electrolyte 
deficient (CLED) agar. Culture plates were 
incubated at 37oC for 24 hours. Identification was 
done using Gram staining and confirmatory tests 
were carried out. Antimicrobial susceptibility test 
was carried out using antibiotic discs on Mueller 
Hinton agar. Antibiotic discs used were gentamycin 
(10mcg), cotrimoxazole 25mcg, ciprofloxacin 
(10mcg), ofloxacin (10mcg), norfloxacin (10mcg) 
and pefloxacin (10mcg). Results were interpreted 
according to Clinical and Laboratory Standards 
Institute (CLSI) guidelines [14],. Susceptibility tests 
were classified into two categories – susceptible and  
 
resistant, with all intermediate susceptibility 
classified as resistant. For quality control of 
susceptibility tests, E.coli ATCC 27922 was used.  
Analysis of data was carried out using SPSS version 
14, Chicago IL. Frequency of E.coli  and 
susceptibility results were expressed as 
percentages. 
RESULTS 
There was a total of 906 bacterial isolates within the 
time frame (2005-2009) included in this study. Of 
this 906, E. coli accounted for 23% (211). Frequency 
of the 211 E. coli isolates from various sources is 
shown in Fig. 1. Table 2 shows the prevalence of E. 
coli in the various sources. The total percentage 
susceptibility of levels of  E.coli  to the various 
fluoroquinolones is shown in Table 2. 
The susceptibility trends of E.coli to pefloxacin, 
ciprofloxacin and ofloxacin were similar across the 
five years (Fig 2). The level of norfloxacin 
susceptibility across the five years was below 10% 
with the highest susceptibility level in 2006 at 9.1%. 
Susceptibility to gentamycin was lowest (27.3%) in 
2006 and it kept increasing till it got to its highest 
(81.8%) in 2009. 
 
 
TABLE 1: PREVALENCE OF ESCHERICHIA COLI  




No of E.coli isolates/total no 
 of samples tested 
Urine 33.37 81/243 
Stool 26.56 51/192 
HVS 15.86 59/372 
Urethra 
swab 9.1  2/22 
Wound 15.35  4/26 





TABLE 2: ANTIBIOTIC SUSCEPTIBILITIES OF ALL E. 
COLI  
ISOLATES TO ANTIMICROBIALS UNDER STUDY 
 BETWEEN 2005 AND 2009 
ANTIMICROBIAL % SUSCEPTIBILITY 
OFLOXACIN 108/211 (51.1) 
CIPROFLOXACIN 115/211 (54.7) 
NORFLOXACIN 4/211 (2.2) 
PEFLOXACIN 111/211 (52.5) 
COTRIMOXAZOLE 50/211 (23.7) 












The results show that E. coli is an important 
pathogen in community acquired bacterial 
infections especially in urinary tract infections, 
which accounts for 38.39% of all the E. coli  isolates. 
Its prevalence in urine samples was also high 
33.37%. Prevalence of E.coli in stool samples was 
26.56% and prevalence in high vaginal swab 
samples (HVS) was 15.86%. This could be as 
because of the proximity of the vagina to the anus. 
The results also show similar susceptibility levels 
among the three second generation 
fluoroquinolones, ciprofloxacin (54.7%), pefloxacin 
(52.5%) and ofloxacin (51.1%), included in the 
study. Susceptibility of ciprofloxacin is similar to 
that found in a study carried out in Tehran [15].
FIG 1: FREQUENCY OF  ESCHERICHIA COLI FROM VARIOUS SOURCES. 
 
 




















































Ciprofloxacin susceptibility was the highest. This is 
also in line with a study carried out in France [16] . 
Susceptibility to gentamycin (51.8%) was also 
similar to that of the fluoroquinolones. However, 
there was poor susceptibility to cotrimoxazole and 
norfloxacin. Susceptibility levels for cotrimoxazole 
in this study  was 23.7%. This is similar to other 
studies carried out in other places [11,17]. Poor 
susceptibility of E.coli  to cotrimoxazole could 
possibly be as a result of the fact that it has been in 
use for a long time, hence giving organisms time to 
develop resistance mechanisms towards it. 
Susceptibility  of E. coli to norfloxacin was quite 
low,  2.2%  with the highest susceptibility of 
norfloxacin being 9.1% in 2006. This is contrary to 
the result obtained from a similar study carried out 
in rural Tamilinadu where susceptibility to 
norfloxacin was 94.44% [18]. According to reports 
published in 2000, quinolone susceptibility was 
greater than 95% [12,19].  Generally, the 
susceptibility levels got in this study is lower than 
that got from previous studies carried out in 
developed countries [20] . This could possibly be 
because of the ease of access to antibiotics over the 
counter in Nigeria, which is also the case in many 
other resource poor settings with lax policies, 
resulting in high and uncontrolled consumption of 
antibiotics. There has been a steady increase in the 
level of resistance of commonly used antibiotics. 
Ciprofloxacin, ofloxacin and pefloxacin were almost 
at par with susceptibility of just over 50%.. In the 
rural Tamilinadu study, antimicrobial susceptibility 
of E.coli from urine isolates to ciprofloxacin was 
77.7% [18]. 
The susceptibility trends across the five years show 
an increase in susceptibility levels of ciprofloxacin, 
ofloxacin and pefloxaciin. In 2007, susceptibility of 
ciprofloxacin increased from 35.7% in 2005 to 67.3% 
in 2007; that of ofloxacin increased from 21.4% in 
2005 to 61.8% in 2007 while that of pefloxacin 
increased from 7.1% in 2005 to 67.3% after which 
the susceptibility levels started dipping again. This 
could possibly be due to a reduction in its use prior 
to 2007 and the subsequent increase in resistance 
after 2007 might have arisen as a result of increased 
use. However, this cannot clearly be ascertained 
from this study. It was also observed that the 
susceptibility levels of gentamycin, an 
aminoglycoside, increased (27.3% in 2006 and 81.8% 
in 2009) as susceptibility levels of the 
fluoroquinolones were reducing.  It should be 
recommended that antibiotic use be rotated. 
Antibiotic cycling which is the rotation of 
antibiotics over a stipulated time period is an 
important aspect in antibiotic stewardship. A study 
in Greece [1] showed significant increase in the 
susceptibility of three important Gram negative 
pathogens to ciprofloxacin following an eighteen 
month restriction on the empirical use of 
fluoroquinolones in the intensive care units. 
High level resistance to these fluoroquinolones in 
this setting might be because of the high level of 
empiric use of antibiotics as a result of inadequate 
laboratory facilities, incomplete and wrong usage of 
antibiotics, high level of abuse as a result of over the 
counter acquisition of antibiotics and the possibility 
of having substandard drugs in the market [21]. 
More studies should be carried out to determine the 
relationship between level of consumption of these 
fluoroquinolones and the level of resistance.  
There is need for constant antimicrobial 
surveillance to detect emerging antibiotic resistance 
patterns. This is also important in the development 
of hospital antibiograms in order to facilitate the 
use of the right antibiotics for the treatment of 
bacterial infections at the local level. Also in 
Nigeria, where over the counter acquisition of 
antibiotics have been implicated as one of the 
reasons for the development of resistance [6], 
policies should be put in place to control this. This 
will help curb the scourge of bacterial resistance. 
The introduction of electronic laboratory databases 
which can be analysed with the help of simple 
software packages such as the WHONET software 
which can be obtained free from World Health 
Organisation [22], will greatly help in antibiotic 
surveillance. 
Conclusion 
This study has shown that E.coli is a predominant 
bacterial pathogen in community acquired bacterial 
infections. There is also a high level of resistance of 
E.coli to fluoroquinolones in the community. 
Inasmuch as there is reasonable level of resistance 
to fluoroquinolones, they will still be useful in the 
management of urinary tract infections, because 
they are excreted in the urine unchanged, hence 
enhancing their effects and E.coli has been indicated 
as the most common pathogen in urinary tract 
infections. However, for other sites, it is 
recommended that fluoroquinolones should not be 
used for empiric treatment. Proper laboratory tests 
should be carried out to determine pathogenic 
organism and sensitivity profile. Furthermore, there 
is need to set up proper antimicrobial surveillance 
systems in health institutions through which 
hospital antibiograms will be developed. Antibiotic 
cycling should also be implemented to help slow 
the rate of resistance development. Further studies 
should be carried out in the region to evaluate the 
effect of antibiotic utilization on bacterial resistance. 
COMPETING INTERESTS: None 
AUTHORS’ CONTRIBUTIONS:  COE and NCO 
designed the study protocol, NCO and OIE carried 
out the analysis and interpretation of data. NCO 





approved the final manuscript. NCO and OIE are 
the guarantors of the paper. 
ACKNOWLEDGEMENT: The authors wish to 
appreciate Mr Larry who assisted in data collection. 
REFERENCES
[1] P.G. Ntagiopoulos , E. Paramythiotour, A. 
Antoniadour ,H. Giamarellou, A. Karabinis. 
“Impact of an antibiotic restriction policy on 
the antibiotic resistance patterns of Gram-
negative microorganisms in an Intensive 
Care Unit in Greece”, Int J  Antimicrob 
Agents , Vol 30, 2007,pp. 360 – 365 
[2] P. Hsueh, P.E. Badal, S.P Hawser, D.J 
Hoban, S.K Bouchillon, Y. Ni et al, 
‘Epidemiology and antimicrobial 
susceptibility profiles of aerobic and 
facultative Gram-negative bacilli isolated 
from patients with intra-abdominal 
infections in the Asia-Pacific region: 2008 
results from SMART (Study for Monitoring 
Antimicrobial Resistance Trends)’, Int J 
Antimicrob Agents , Vol 36, 2010, pp. 408 – 
414. 
[3] J.L. Crandon, J.L Kuti, R.N. Jones, D.P. 
Nicolau, ‘Comparison of 2002-2006 
OPTAMA progress for US hospitals: focus 
on Gram-negative resistance’, Ann 
Pharmacother , Vol 43, 2009, pp. 220 - 227 
[4] W.C Ko, P.R Hsueh, ‘Increasing extended 
spectrum β-lactamase production and 
quinolone resistance among Gram-negative 
bacilli causing intra-abdominal infections in 
the Asia-Pacific region: data from SMART 
study 2002 – 2006’, J Infect, Vol 59, 2009, pp. 
95 - 103 
[5] S. Njissen, A. Florijn, M.J. Binten, F.J. 
Schmitz, J. Verhoef, A.C. Flut, ‘Β-lactam 
susceptibilities and prevalence of ESBL 
producing isolates among more than 5000 
European Enterobacteriaceae isolates’, Int J 
Antimicrob Agents, Vol 24, 2004, pp. 585 - 
591 
[6] I.N. Okeke, K.P. Klugman, Z.A. Bhutta, 
G.D. Adriano, P. Jenkins, T. O’Brien et al. 
“Antimicrobial resistance in developing 
countries 2: Strategies for containment” 
Lancet Infect Dis , Vol 5, 2005, pp. 568 – 80 
[7] T.M. Hooton, R. Besser, B. Foxman, T.R. 
Fritsche, L.E. Nicolle, “Acute 
uncomplicated cystitis in an era of 
increasing antibiotic resistance: A proposed 
approach to empirical therapy”, Clin Infect 
Dis, Vol 39 No.1, 2004, pp. 75 – 80 
[8] K. Gupta, T.M. Hooton, C.L. Wobbe, W.E. 
Stamm, “ The prevalence of antimicrobial 
resistance among uropathogens causing 
acute uncomplicated cystitis in young 
women”,  Int J Antimicrob Agents, Vol 11, 
1999, pp. 305 – 308. 
[9] J.A. Karlowsky, M.E. Jones, C. Thornsberry, 
I. Critchley, I.J. Kelly, D.F. Sahm,  
“Prevalence of antimicrobial resistance 
among urinary tract pathogens isolated 
from female outpatients across the US in 
1999”, Int J Antimicrob Agents, Vol  18, 2001, 
pp. 121 - 127 
[10] J.A.Karlowsky, C. Thornsberry, M.E. Jones, 
D.F. Sahm,  “Susceptibility of antimicrobial 
resistant urinary Escherichia coli isolates to 
fluoroquinolones and nitrofurantoin”,  Clin 
Infect Dis, Vol 36, 2003, pp. 183 - 187 
[11] J.A. Karlowsky, I.J Kelly, C. Thornsberry, 
M.E. Jones, D.F. Sahm, “Trends in 
antimicrobial resistance among urinary 
tract infection isolates of  Escherichia coli 
from female outpatients in the United 
States”, Antimicrob Agents Chemother, Vol 46, 
2002, pp.  2540 - 2545 
[12]  J.A. Karlowsky, I.J. Kelly, C. Thornsberry, 
M.E. Jones, A.T. Evangelista, I.A. Critchley 
et al, “Susceptibility to fluoroquinolones 
among commonly isolated Gram-negative 
bacilli in 2000: TRUST and TSN data for the 
United States” Int J Antimicrob Agents, Vol 
19, 2002, pp. 21 – 31 
[13] Y. Karaca, N. Coplu, A. Gozalan, O. Oncul, 
E. Citil, B. Esen. “Co-trimoxazole and 
quinolone resistance in  Escherichia coli 
isolated from urinary tract infections over 
the last 10 years” Int J of Antimicrob Agents, 
Vol 26, 2005, pp 75 – 77. 
[14] Clinical and Laboratory Standards Institute. 
Performance standards for antimicrobial 
susceptibility tests, 21st informational 
supplement, Vol 31 No.1,2011. 
[15] N. Kashef, G.E. Djavid, S. Shalbazi, 
“Antimicrobial susceptibility patterns of 
community acquired uropathogens in 
Tehran, Iran”, J Infect Dev Countries, Vol 4 
No.4, 2010, pp. 202 – 206. 
[16] S. Thibaut, J. Caillon, C. Huart, G. 
Grandjean, P. Lombrall, G. Potel G et al, 
“Susceptibility to the main antibiotics of 





strains identified in community acquired 
infections in France. (MedQual 2004 – 
2007)”, Medicine et Maladies Infectieuses, Vol 
40, 2010, pp. 74 – 80 
[17] K.T. Wariso, I.M. Siminialayi, J.O. Odigie, 
“Pattern and antibiogram of urinary tract 
infection at the University of Port Harcourt 
Teaching Hospital”, Asian Pacific Journal of 
Tropical Medicine 2010, 1-5 
[18] A. Manpand, A.A. Al-Salamah, M. 
Amuthan, “ Prevalence and antibiotic 
susceptibility of uropathogens in patients 
from a rural environment, Tamilnadu”,  Am 
J Infect Dis Vol 6(2), 2010, pp. 29 – 33 
[19] M. Chomarat, “ Resistance of bacteria in 
urinary tract infections”, Int J Antimicrob 
Agents,, Vol 16, 2000, pp. 483 – 7 
[20] G.C. Schito , “Why fosfomycin trometamol 
as first line therapy for uncomplicated 
urinary tract infections”, Int J of Antimicrob 
Agents, Vol  22(2), 2003, pp. 79 – 83 
[21] A. Raufu, “ Influx of fake drugs to Nigeria 
worries health experts”, BMJ, Vol 324, 2000, pp.698. 
[22] D.L. Monnet, “Toward multinational 
antimicrobial resistance surveillance 
systems in Europe”, Int J Antimicrob Agents, 
Vol 15, 2000 pp. 91 - 101  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
